Objective: In our study we aimed to investigate the role of fetuin-A, a systemic calcification inhibitor, and osteopontin, which plays an important role in calcification processes, in the pathogenesis of urinary tract stone disease.

Materials and Methods: Our study group included 111 patients diagnosed with nephrolithiasis and 66 healty volunteers. Serum and urine calcium, phosphorus, magnesium, uric acid, creatinine levels and urine oxalate, citrate, fetuin-A, osteopontin and GAG levels are determined in all individuals. Stone analysis has been performed, if available.

Results: Urine osteopontin levels in the patient group has been found to be significantly lower compared with control group. There was no difference between control and patient group in terms of urine fetuin-A levels. In patient group urine oxalate and calcium levels were higher and urine citrate levels and urine GAG/creatinine ratio was lower compared with control group. Although there was no significant correlation between fetuin-A and urine calcium, phosphorus, magnesium, uric acid, oxalate, citrate, GAG levels, there was a weak statistically significant positive relationship between urine osteopontin and magnesium levels.

Conclusion: New studies are needed that use of osteopontin and fetuin A in diagnosis and follow up of nephrolithiasis